Remoxy’s "Complete Response" Letter Has No Clear Culprit But Many Suspects
This article was originally published in Pharmaceutical Approvals Monthly
Legal and safety issues continue to swirl around Pfizer and Pain Therapeutics’ Remoxy as it deals with the product’s second “complete response” letter in less than three years.
You may also be interested in...
FDA okays the opioid, which contains abuse-resistant components, with labeling about a study that found the drug less likeable than immediate-release oxycodone.
FDA’s response to new data on Remoxy could serve as a model for how the agency expects to deal with the abuse-deterrent formulations it is encouraging for oxycodone and other opioids.
Congress and FDA already are sparring over the drug companies’ mandate to pay for the prescriber education included in the national prescription drug abuse plan.